Abstract: Objective This study was conducted to investigate clinical efficacy of esophageal variceal ligation (EVL) with auxiliary oral thrombin and intravenous octreotide administration in the treatment of cirrhotics with esophageal and gastric variceal bleeding (EGVB). Method 120 patients with liver cirrhosis (LC) complicated with EGVB were admitted to our hospital between June 2021 and June 2023, and among them, 60 patients in observation received EVL with auxiliary oral thrombin powder and intranenous octreotide administration, and another 60 patients in control received EVL and octreotide infusion. Medical treatment continued for 1 week, and all patients in the two groups were followed-up for three months. Wedged hepatic vein pressure (WHVP) and free hepatic vein pressure (FHVP) were measured by through jugular vein approach for calculation of hepatic vein pressure gradient (HVPG). Result At end of one week treatment, two and eight patients in the observation and control died, with successful hemostasis of 96.7% in the observation group, much higher than 86.7%(P＜0.05) in the control; among survivals, early and delayed rebleeding and disappearance of varies in the observation were 22.4%, 17.2% and 69.0%, all not significantly different compared to 16.7%, 13.3% and 73.1% (P>0.05) in the control; after treatment, HVPG in the observation was (19.1±2.6)mmHg, not significantly different compared to (19.0±3.0)mmHg in the control (P>0.05); at admission and after treatment, there were no significant differences as respect to hepatic and renal function tests in the two groups (P>0.05). Conclusion The EVL with auxiliary treatment of oral thrombin powder and intranenous octreotide maintenance in the treatment of patients with EGVB has a good efficacy, with ascertainable hemostatic effect and prevention of rebleeding.

Key words: Liver cirrhosis, Esophageal and gastric variceal bleeding, Endoscopic variceal ligation, Thrombin powder, Octreotide, Therapy